Medicare forces insurers to put cheap drugs first, blocking gatekeeping tactics

What it does

This bill requires Medicare prescription drug plans (Part D) to include cheaper generic drugs and biosimilar medications on their formularies in preferred positions (lower cost tiers) starting in 2027, and prohibits insurers from using prior authorization or step therapy to make these cheaper drugs harder to access than their brand-name equivalents. The goal is to lower out-of-pocket costs for seniors by ensuring they can easily choose lower-cost alternatives.

Why we flagged it

The bill's operative mechanism is a direct mandate on insurers to prioritize cheaper drugs and restrict their ability to use administrative barriers to steer patients toward expensive alternatives. This is a consumer-protection / affordability measure, not a subsidy or deregulation.

What the text implies

• Formulary tier placement is now constrained by cost comparison, potentially reducing insurer flexibility in negotiating rebates or managing utilization — insurers may respond by raising premiums or narrowing networks.
• The 'preferred position' requirement may increase generic/biosimilar utilization rates, which could reduce brand-drug market share and manufacturer revenue, though this is the bill's stated intent.
• Prior authorization and step therapy restrictions on cheaper drugs may shift administrative burden from insurers to pharmacies and providers, with unclear cost pass-through.
• The rule applies only to drugs where generics/biosimilars cost less than brand drugs — it does not address cases where generic prices have risen above brand prices, a known market phenomenon.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Seniors gain direct access to lower-cost generic and biosimilar drugs without insurer-imposed barriers, reducing out-of-pocket spending and improving medication affordability. The bill restricts insurer discretion to steer patients toward more expensive brand drugs through administrative gatekeeping.

Who stands to gain

• Medicare beneficiaries (seniors)
• generic drug manufacturers
• biosimilar manufacturers

Named in the bill

Medicare Part D, PDP sponsors, generic drug manufacturers, biosimilar manufacturers, brand pharmaceutical companies, CMS (Centers for Medicare & Medicaid Services)

Where it stands

2 cosponsors: 1 Democrats, 1 Republicans.

• Mar 27, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 27, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 4 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $5,867,990 in lobbying spend. A filing names 28 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Doris Matsui, the sponsor, reported $1,026,688 in PAC receipts in the 2026 cycle. $1,000 of that came from 1 PAC tied to these lobbying clients.

• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Prime Therapeutics — $100,000 on 1 filing
• Internet Works — $45,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.